Evolution in psoriasis management

Evolution in psoriasis management

Bibliographic Details
Main Author:	Steven R. Feldman
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-04-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2017.1326659

Similar Items

Rethinking the costs of psoriasis management
by: Steven R. Feldman
Published: (2017-10-01)

Should the presence of psoriatic arthritis change how we manage psoriasis?
by: Warren H. Chan, et al.
Published: (2021-11-01)

Implications of treatment resistant severe psoriasis for benchmarking quality of care
by: Steven R. Feldman
Published: (2017-08-01)

Review of bimekizumab in the treatment of psoriasis
by: Sindhuja Koppu, et al.
Published: (2022-11-01)

SECURE-Psoriasis: a de-identified registry of psoriasis patients diagnosed with COVID-19
by: Esther A. Balogh, et al.
Published: (2020-05-01)

Choice Overload in Systemic Psoriasis Therapy
by: Patrick A. Whitman, et al.
Published: (2019-02-01)

Assessing Efficacy and the Speed of Response in Psoriasis Treatment
by: Jeremy G. Light, et al.
Published: (2019-08-01)

Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management
by: Katherine A. Kelly, et al.
Published: (2021-08-01)

Our ambition in a changing landscape of psoriasis treatments
by: Peter C. M. van de Kerkhof, et al.
Published: (2020-02-01)

Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis
by: Mohammed D. Saleem, et al.
Published: (2018-01-01)

When should systemic biologic therapy for psoriasis be discontinued?
by: Diem-Phuong D. Dao, et al.
Published: (2023-01-01)

Navigating Challenges and Advances in Pediatric Psoriasis and Atopic Dermatitis Treatment
by: Katie K. Lovell, et al.
Published: (2023-12-01)

Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?
by: Joeseph Nenow, et al.
Published: (2021-11-01)

The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
by: Rohan Singh, et al.
Published: (2021-11-01)

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
by: Megan Hohenberger, et al.
Published: (2018-01-01)

Psoriasis clearance rates with different treatments – An In-depth retrospective chart review
by: Katie Lovell, et al.
Published: (2023-01-01)

The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis
by: Ali Rajabi-Estarabadi, et al.
Published: (2018-02-01)

Is topical treatment effective for psoriasis in patients who failed topical treatment?
by: Nwanneka Okwundu, et al.
Published: (2021-01-01)

Comparing psoriasis advertisement methods with patient willingness to initiate treatment
by: Jeremy K. Bray, et al.
Published: (2020-08-01)

The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options
by: Heli A. Patel, et al.
Published: (2023-08-01)

Differences in healthcare barriers based on racial and/or ethnic background for patients with psoriasis
by: Jeremy K. Bray, et al.
Published: (2021-08-01)

Epidemiology of mental health comorbidity in psoriasis
by: J. J. Wu, et al.
Published: (2018-07-01)

Management of Pediatric Psoriasis: A U.S. Survey Based on Visits from the National Ambulatory Medical Care Survey (NAMCS)
by: Rachel E. Tao, et al.
Published: (2023-10-01)

Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial
by: Mohammed D. Saleem, et al.
Published: (2018-01-01)

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
by: Rachel C. Ruda, et al.
Published: (2023-12-01)

Differential access to psoriasis biologic information in English and Spanish
by: Max Oscherwitz, BS, et al.
Published: (2024-06-01)

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
by: Jashin J. Wu, et al.
Published: (2020-04-01)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-03-01)

Psoriasis patient preferences for topical drugs: a systematic review
by: Mathias Tiedemann Svendsen, et al.
Published: (2021-07-01)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023-09-01)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022-03-01)

Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials
by: Steven R. Feldman, et al.
Published: (2021-10-01)

Internet-based survey intervention improves adherence to methotrexate among psoriasis patients
by: Abigail Cline, et al.
Published: (2022-08-01)

Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States
by: Jashin J. Wu, et al.
Published: (2018-11-01)

Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis
by: A. L. Bakulev
Published: (2019-02-01)

Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population
by: Bingcao Wu, et al.
Published: (2021-08-01)

Phosphodiesterase-4 Inhibition in the Management of Psoriasis
by: Erika L. Crowley, et al.
Published: (2023-12-01)

Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population
by: Chang Xu, et al.
Published: (2022-05-01)

Skin Disease in Children: Effects on Quality of Life, Stigmatization, Bullying, and Suicide Risk in Pediatric Acne, Atopic Dermatitis, and Psoriasis Patients
by: Katherine A. Kelly, et al.
Published: (2021-11-01)